Dr. Martens (LON:DOCS) Shares Down 12.4% – Here’s Why

Dr. Martens plc (LON:DOCS) was down 12.4% on Tuesday . The stock traded as low as GBX 65 and last traded at GBX 66.30. Approximately 4,229,807 shares changed hands during mid-day trading, an increase of 138% from the average daily volume of 1,776,838 shares. The stock had previously closed at GBX 75.65.

Analysts Set New Price Targets

DOCS has been the topic of a number of analyst reports. Peel Hunt reiterated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of GBX 6,000.

Dr. Martens Stock Performance

The stock has a fifty day simple moving average of GBX 75.88 and a 200-day simple moving average of GBX 83.26. The stock has a market cap of £657.97 million, a P/E ratio of 40.04, a PEG ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85.

Dr. Martens (LON:DOCS) last posted its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. On average, equities analysts expect that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Insider Activity

In other Dr. Martens news, insider Robert Hanson bought 96,000 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were acquired at an average cost of GBX 79 per share, with a total value of £75,840. Insiders purchased 97,130 shares of company stock valued at $7,673,816 over the last ninety days. Company insiders own 2.79% of the company’s stock.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.